Dominant-negative tumor necrosis factor protects from mycobacterium bovis Bacillus Calmette-Guérin (BCG) and endotoxin-induced liver injury without compromising host immunity to BCG and mycobacterium tuberculosis

Journal of Infectious Diseases

Volumn 199, Issue 7, 2009, Pages 1053-1063

  Olleros, Maria L ^a   Vesin, Dominique ^a   Lambou, Agathe F ^a   Janssens, Jean Paul ^b   Ryffel, Bernhard ^c   Rose, Stéphanie ^c   Frémond, Cécile ^c   Quesniaux, Valérie F ^c   Szymkowski, David E ^d   Garcia, Irene ^a,e  

^a Inst de Med Social et Prev   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c CNRS   (France)

^d Xencor Inc   (United States)

^e UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIINFLAMMATORY AGENT; ASPARTATE AMINOTRANSFERASE; BCG VACCINE; ENDOTOXIN; ETANERCEPT; GAMMA INTERFERON; INTERLEUKIN 12P70; INTERLEUKIN 4; INTERLEUKIN 6; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; XENP 1595; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; LIPOPOLYSACCHARIDE; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ACUTE HEPATITIS; AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; EXPERIMENTAL MODEL; IMMUNE DEFICIENCY; INNATE IMMUNITY; LIVER GRANULOMA; LIVER INJURY; LIVER PROTECTION; MOUSE; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; TUBERCULOSIS; ANIMAL; C57BL MOUSE; CELL LINE; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; IMMUNOLOGY; LIVER DISEASE; LUNG; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY;

ANIMALS; CELL LINE; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; LIPOPOLYSACCHARIDES; LIVER DISEASES; LUNG; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; RECEPTORS, TUMOR NECROSIS FACTOR; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 65549150310     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/597204     Document Type: Article

References (46)

1. Blam ME, Stein RB, Lichtenstein GR. Integrating anti-tumor necrosis factor therapy in inflammatory bowel disease: current and future perspectives. Am J Gastroenterol 2001; 96:1977-97.
2. Criscione LG, St Clair EW. Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases. Curr Opin Rheumatol 2002; 14: 204-11.
3. Haraoui B. Differentiating the efficacy of the tumor necrosis factor inhibitors. Semin Arthritis Rheum 2005; 34:7-11.
4. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008; 117:244-79.
5. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345:1098-104.
6. Ehlers S. Role of tumour necrosis factor (TNF) in host defence against tuberculosis: implications for immunotherapies targeting TNF. Ann Rheum Dis 2003; 62(Suppl 2):ii37-42.
7. Blam ME, Stein RB, Lichtenstein GR. Integrating anti-tumor necrosis factor therapy in inflammatory bowel disease: current and future perspectives. Am J Gastroenterol 2001; 96:1977-97.
8. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004; 38:1261-5.
9. Long M, Higgins AD, Mihalyo MA, Adler AJ. Effector CD4 cell tolerization is mediated through functional inactivation and involves preferential impairment of TNF-alpha and IFN-gamma expression potentials. Cell Immunol 2003; 224:114-21.
10. Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human antitumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004; 50:1400-11.
11. Kindler V, Sappino AP, Grau GE, Piguet PF, Vassalli P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989; 56:731-40.
12. Adams LB, Mason CM, Kolls JK, Scollard D, Krahenbuhl JL, Nelson S. Exacerbation of acute and chronic murine tuberculosis by administration of a tumor necrosis factor receptor-expressing adenovirus. J Infect Dis 1995; 171:400-5.
13. Flynn JL, Goldstein MM, Chan J, et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995; 2:561-72.
14. Garcia I, Miyazaki Y, Marchal G, Lesslauer W, Vassalli P. High sensitivity of transgenic mice expressing soluble TNFR1 fusion protein to mycobacterial infections: synergistic action of TNF and IFN-gamma in the differentiation of protective granulomas. Eur J Immunol 1997; 27:3182-90.
15. Bean AG, Roach DR, Briscoe H, et al. Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J Immunol 1999; 162:3504-11.
16. Bopst M, Garcia I, Guler R, et al. Differential effects of TNF and LTalpha in the host defense against M. bovis BCG. Eur J Immunol 2001; 31:1935-43.
17. Botha T, Ryffel B. Reactivation of latent tuberculosis infection in TNFdeficient mice. J Immunol 2003; 171:3110-8.
18. Guler R, Olleros ML, Vesin D, Parapanov R, Garcia I. Differential effects of total and partial neutralization of tumor necrosis factor on cell-mediated immunity to Mycobacterium bovis BCG infection. Infect Immun 2005; 73:3668-76.
19. Plessner HL, Lin PL, Kohno T, et al. Neutralization of tumor necrosis factor (TNF) by antibody but not TNF receptor fusion molecule exacerbates chronic murine tuberculosis. J Infect Dis 2007; 195:1643-50.
20. Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997; 385: 729-33.
21. Moss ML, Jin SL, Milla ME, et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 1997; 385:733-6.
22. Olleros ML, Guler R, Corazza N, et al. Transmembrane TNF induces an efficient cell-mediated immunity and resistance to Mycobacterium bovis bacillus Calmette-Guerin infection in the absence of secreted TNF and lymphotoxin-alpha. J Immunol 2002; 168:3394-401.
23. Olleros ML, Guler R, Vesin D, et al. Contribution of transmembrane tumor necrosis factor to host defense against Mycobacterium bovis bacillus Calmette-Guerin and Mycobacterium tuberculosis infections. Am J Pathol 2005; 166:1109-20.
24. Fremond C, Allie N, Dambuza I, et al. Membrane TNF confers protection to acute mycobacterial infection. Respir Res 2005; 6:136.
25. Saunders BM, Tran S, Ruuls S, Sedgwick JD, Briscoe H, Britton WJ. Transmembrane TNF is sufficient to initiate cell migration and granuloma formation and provide acute, but not long-term, control of Mycobacterium tuberculosis infection. J Immunol 2005; 174:4852-9.
26. Ruuls SR, Hoek RM, Ngo VN, et al. Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation. Immunity 2001; 15:533-43.
27. Steed PM, Tansey MG, Zalevsky J, et al. Inactivation of TNF signaling by rationally designed dominant-negative TNF variants. Science 2003; 301: 1895-8.
28. Zalevsky J, Secher T, Ezhevsky SA, et al. Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection. J Immunol 2007; 179:1872-83.
29. Scallon B, Cai A, Solowski N, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002; 301:418-26.
30. Agnholt J, Dahlerup JF, Kaltoft K. The effect of etanercept and infliximab on the production of tumour necrosis factor alpha, interferongamma and GM-CSF in in vivo activated intestinal T lymphocyte cultures. Cytokine 2003; 23:76-85.
31. Mitoma H, Horiuchi T, Tsukamoto H. Binding activities of infliximab and etanercept to transmembrane tumor necrosis factor-alpha. Gastroenterology 2004; 126:934-5; author reply 935-6.
32. Mitoma H, Horiuchi T, Hatta N, et al. Infliximab induces potent antiinflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. Gastroenterology 2005; 128:376-92.
33. Shen C, Assche GV, Colpaert S, et al. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther 2005; 21:251-8.
34. McCoy MK, Martinez TN, Ruhn KA, et al. Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease. J Neurosci 2006; 26:9365-75.
35. Wooley PH, Dutcher J, Widmer MB, Gillis S. Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. J Immunol 1993; 151:6602-7.
36. Joosten LA, Helsen MM, van de Loo FA, van den Berg WB. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra. Arthritis Rheum 1996; 39:797-809.
37. Coppieters K, Dreier T, Silence K, et al. Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collageninduced arthritis. Arthritis Rheum 2006; 54:1856-66.
38. FremondCM,Yeremeev V, NicolleDM,Jacobs M, Quesniaux VF, Ryffel B. Fatal Mycobacterium tuberculosis infection despite adaptive immune response in the absence of MyD88. J Clin Invest 2004; 114:1790-9.
39. Guler R, Olleros ML, Vesin D, et al. Inhibition of inducible nitric oxide synthase protects against liver injury induced by mycobacterial infection and endotoxins. J Hepatol 2004; 41:773-81.
40. Garcia I, Guler R, Vesin D, et al. Lethal Mycobacterium bovis bacillus Calmette Guerin infection in nitric oxide synthase 2-deficient mice: cell-mediated immunity requires nitric oxide synthase 2. Lab Invest 2000; 80:1385-97.
41. Borsotti C, Franklin AR, Lu SX, et al. Absence of donor T-cell-derived soluble TNF decreases graft-versus-host disease without impairing graft-versus-tumor activity. Blood 2007; 110:783-6.
42. Lucas R, Tacchini-Cottier F, Guler R, et al. A role for lymphotoxin beta receptor in host defense against Mycobacterium bovisBCGinfection. Eur J Immunol 1999; 29:4002-10.
43. Ehlers S, Holscher C, Scheu S, et al. The lymphotoxin beta receptor is critically involved in controlling infections with the intracellular pathogens Mycobacterium tuberculosis and Listeria monocytogenes. J Immunol 2003; 170:5210-8.
44. Marino S, Sud D, Plessner H, et al. Differences in reactivation of tuberculosis induced from anti-TNF treatments are based on bioavailability in granulomatous tissue. PLoS Comput Biol 2007; 3:1909-24.
45. Wallis RS. Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade. Arthritis Rheum 2008; 58:947-52.
46. Spohn G, Guler R, Johansen P, et al. A virus-like particle-based vaccine selectively targeting soluble TNF-alpha protects from arthritis without inducing reactivation of latent tuberculosis. J Immunol 2007; 178:7450-7.